The U.S. cancer biopsy market is expected to reach USD 20.18 billion by 2030, registering a CAGR of 11.12% from 2023 to 2030. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.
The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.
Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.
Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.
Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.
Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.
The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.
Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.
Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.
Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.
Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.
U.S. Cancer Biopsy Market Report Highlights
- Fine-needle aspiration segment held a dominant share in 2022 owing to the effective and quick test for determining the status of uncertain tissue
- Pharma & biopharma discovery & development segment is projected to grow at the fastest rate during the forecast period owing to the increasing demand for developing novel drug candidates
- Breast cancer segment is the highest revenue-generating segment in the U.S. cancer biopsy market in 2022 owing to the increasing prevalence of breast cancer
- North America dominated the U.S. cancer biopsy market in 2022, which is attributed to preventive measures undertaken by the governments to stop the progression of diseases
Table of Contents
Chapter 1 Methodology and Scope1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Internal Database
1.4.3 Secondary Sources
1.4.3.1 Primary Research
1.4.4 Details Of Primary Research
1.5 Information Or Data Analysis
1.5.1 Data Analysis Models
1.5.1.1 End-Use Landscape Assessment
1.5.1.2 Market Origin Assessment
1.5.1.3 Oncology Diagnosis: Market Competition Analysis
1.6 Market Formulation And Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.8 U.S. Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Market Variables, Trends, and Scope
3.1 Cancer Medical Tourism Within & Outside the U.S.
3.2 Market Driver Analysis
3.2.1 Advent Of Liquid Biopsy
3.2.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
3.2.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
3.3 Market Restraint Analysis
3.3.1 Risks Associated With Biopsy Procedures
3.3.2 Technical And Clinical Challenges
3.4 Market Opportunity Analysis
3.4.1 Integral Role Of Biopsies In Oncology Companion Diagnostics
3.4.2 Increase In The Demand For Biopsies In Translational Research
3.5 Market Threat Analysis
3.5.1 Risk Associated With Repeat Biopsy Procedures
Chapter 4 Business Environment Analysis
4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
4.2 Porter’s Five Forces Analysis
Chapter 5 Supply Chain Analysis
5.1 Sample Collection (List of Biobanks/Center)
5.2 Sample Processing (List of Vendors)
Chapter 6 Cost/Pricing Analysis
6.1 Biopsy Cost
6.1.1 By Indication
6.1.1.1 Typical Biopsy Costs For Patients Not Covered By Health Insurance In The U.S.
6.1.2 By Type/Method
6.2 Key Factors Influencing The Cost
6.3 Costs Of Cancer Management
6.3.1 Pharma Versus Diagnostics Price Analysis For Cancer Care
6.3.2 U.S. Expenditures For Cancer By Source Of Payment
6.3.2.1 Expenditures For Cancer Care By Year & Cancer Site, USD Million, 2010 - 2018
Chapter 7 Reimbursement And Regulatory Analysis
7.1 Regulatory Framework: U.S. Cancer Biopsy Market
7.2 Reimbursement Framework: U.S. Cancer Biopsy Market
Chapter 8 Challenges/Restraints/Complications Analysis
8.1 Challenges/Restraints/Complications Analysis
8.1.1 By Site (Organ)
8.1.2 By Method
Chapter 9 Cancer Biopsy Product Manufacturers
Chapter 10 Type Business Analysis
10.1 U.S. Cancer Biopsy Market: Type Movement Analysis
10.2 U.S. Cancer Biopsy Market: Comparative Analysis of Biopsy Type
10.3 Fine Needle Aspiration
10.4 Core Needle Biopsy (CNB)
10.4.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.4.1.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
10.4.1.2 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
10.5 Cancer Surgical Biopsy
10.5.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.5.1.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
10.5.1.2 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
10.6 Skin Biopsy/Punch Biopsy
10.6.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.1.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
10.6.1.2 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
10.6.1.3 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
10.6.1.4 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
10.6.1.5 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
10.7 Others
10.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Types, 2018 - 2030 (USD Million)
10.7.1.1 U.S. other types cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
10.7.1.2 U.S. other types cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
Chapter 11 Site (Organ) Business Analysis
11.1 Cancer Biopsy Market: Site (Organ) Movement Analysis
11.2 Breast
11.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Breast, 2018 - 2030 (USD Million)
11.3 Thyroid
11.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Thyroid, 2018 - 2030 (USD Million)
11.4 Uterus & Cervix
11.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Uterus & Cervix, 2018 - 2030 (USD Million)
11.5 Lung
11.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Lung, 2018 - 2030 (USD Million)
11.6 Prostate
11.6.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Prostate, 2018 - 2030 (USD Million)
11.7 Bladder
11.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Bladder, 2018 - 2030 (USD Million)
11.8 Kidney
11.8.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Kidney, 2018 - 2030 (USD Million)
11.9 Liver
11.9.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Liver, 2018 - 2030 (USD Million)
11.10 Pancreas
11.10.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pancreas, 2018 - 2030 (USD Million)
11.11 Other Sites
11.11.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Sites, 2018 - 2030 (USD Million)
Chapter 12 Application (Cause) Business Analysis
12.1 U.S. Cancer Biopsy Market: Application (Cause) Movement Analysis
12.2 Screening & Monitoring
12.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Screening & Monitoring, 2018 - 2030 (USD Million)
12.3 Diagnostics
12.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Diagnostics, 2018 - 2030 (USD Million)
12.4 Investigational & Translational Research
12.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Investigational & Translational Research, 2018 - 2030 (USD Million)
12.5 Pharma & Biopharma Discovery & Development
12.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pharma & Biopharma Discovery & Development, 2018 - 2030 (USD Million)
Chapter 13 Regional Business Analysis
13.1 U.S. Cancer Biopsy Market: Regional Movement Analysis
13.2 U.S.
13.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)
Chapter 14 Competitive Landscape
14.1 Market Participation Categorization
14.2 Strategy Framework
14.3 Vendor Landscape
14.3.1 List Of Key Distributors And Channel Partners
14.3.2 Key Customers
14.3.2.1 List Of Key Customers
14.3.3 Public Companies
14.3.3.1 List Of Public Companies
14.3.4 Private Companies
14.3.4.1 List Of Key Private Companies
14.3.5 Emerging Players
14.3.5.1 List Of Key Emerging Companies
14.4 Major Deals And Strategic Alliances Analysis
14.4.1 Mergers And Acquisitions
14.4.2 Collaborations And Partnerships
14.4.3 New Product Launch
14.5 Market Impact Analysis By Key Participants
14.5.1 Ansoff Matrix
14.5.2 Company/Competition Categorization (Primary & Secondary Market Participants)
Chapter 15 Company Profiles
15.1 Company Profiles
15.1.1 Bd (Becton, Dickinson And Company)
15.1.1.1 Company Overview
15.1.1.2 Financial Performance
15.1.1.3 Product Benchmarking
15.1.1.4 Strategic Initiatives
15.1.2 Izi Medical Products
15.1.2.1 Company Overview
15.1.2.2 Product Benchmarking
15.1.2.3 Strategic Initiatives
15.1.3 Johnson & Johnson Services, Inc.
15.1.3.1 Company Overview
15.1.3.2 Depuy Synthes
15.1.3.2.1 Company Overview
15.1.3.3 Ethicon, Inc.
15.1.3.3.1 Company Overview
15.1.3.4 Financial Performance
15.1.3.5 Product Benchmarking
15.1.4 Argon Medical
15.1.4.1 Company Overview
15.1.4.2 Product Benchmarking
15.1.4.3 Cook
15.1.4.4 Company Overview
15.1.4.5 Product Benchmarking
15.1.5 Spectra Medical Devices, Inc.
15.1.5.1 Company Overview
15.1.5.2 Product Benchmarking
15.1.6 Medtronic
15.1.6.1 Company Overview
15.1.6.2 Financial Performance
15.1.6.3 Product Benchmarking
15.1.6.4 Strategic Initiatives
15.1.7 Boston Scientific Corporation
15.1.7.1 Company Overview
15.1.7.2 Financial Performance
15.1.7.3 Product Benchmarking
15.1.7.4 Strategic Initiatives
15.1.8 Conmed Corporation
15.1.8.1 Company Overview
15.1.8.2 Financial Performance
15.1.8.3 Product Benchmarking
15.1.9 Inrad, Inc.
15.1.9.1 Company Overview
15.1.9.2 Product Benchmarking
15.1.10 Thermo Fisher Scientific, Inc.
15.1.10.1 Company Overview
15.1.10.2 Financial Performance
15.1.10.3 Product Benchmarking
15.1.10.4 Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 Reasons for the popularity of oncology tourism in some countries
Table 3 Common types of oncology tourism treatments
Table 4 Liquid biopsy developing or commercializing companies
Table 5 Average pricing analysis: Biopsy to indication
Table 6 Average pricing analysis: Biopsy to indication
Table 7 Expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018
Table 8 List of cleared/approved companion diagnostic devices (In vitro and imaging tools)
Table 9 Types of insurance coverage
Table 10 Policy structure types issued by private payers and Medicare
Table 11 Coverage policies for ctDNA
Table 12 CPT codes for minimally invasive prostate procedures
Table 13 CPT codes for office visits-new & established patient
Table 14 Surgical biopsy: Feasibility analysis across cancer diagnosis
Table 15 Comparative analysis of traditional and liquid liver biopsies
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 End-use landscape: Cancer biopsy product penetration
Fig. 5 Cancer biopsy: Market origin/parent market assessment
Fig. 6 Market competition analysis: Early diagnosis industry sector
Fig. 7 Market formulation & validation
Fig. 8 U.S. cancer biopsy market outlook (2022)
Fig. 9 U.S. cancer biopsy market driver impact
Fig. 10 External factors driving the demand for cancer biopsy
Fig. 11 U.S. cancer biopsy market restraint impact
Fig. 12 SWOT analysis
Fig. 13 Porter’s five forces analysis
Fig. 14 Key driving factors of biopsy costs
Fig. 15 U.S. expenditures for cancer by payment source, 2018
Fig. 16 National cancer costs projected to increase drastically by 2030, in USD Billion
Fig. 17 U.S. out-of-pocket expenses 2014 vs. 2018
Fig. 18 U.S. cancer management expenditure
Fig. 19 U.S. cancer biopsy market: Type outlook and key takeaways
Fig. 20 U.S. cancer biopsy market: Type movement analysis
Fig. 21 Tissue biopsy vs liquid biopsy: Comparative analysis
Fig. 22 U.S. cancer core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 U.S. cancer core needle biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
Fig. 24 U.S. cancer core needle biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
Fig. 25 U.S. cancer surgical biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 U.S. cancer surgical biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
Fig. 27 U.S. cancer surgical biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
Fig. 28 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
Fig. 30 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
Fig. 31 U.S. skin biopsy/punch cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 U. S .skin biopsy /punch cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
Fig. 33 U.S. skin biopsy /punch cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
Fig. 34 U.S. cancer liquid biopsy market estimates and forecasts for other types, 2018 - 2030 (USD Million)
Fig. 35 U.S. other types of cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
Fig. 36 U.S. other types of cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
Fig. 37 Cancer biopsy market: Site (Organ) outlook and key takeaways
Fig. 38 Cancer biopsy market: Site (Organ) movement analysis
Fig. 39 U.S. cancer biopsy market estimates and forecasts for breast, 2018 - 2030 (USD Million)
Fig. 40 U.S. cancer biopsy market estimates and forecasts for thyroid, 2018 - 2030 (USD Million)
Fig. 41 U.S. cancer biopsy market estimates and forecasts for uterus & cervix, 2018 - 2030 (USD Million)
Fig. 42 U.S. cancer biopsy market estimates and forecasts for lung, 2018 - 2030 (USD Million)
Fig. 43 U.S. cancer biopsy market estimates and forecasts for prostate, 2018 - 2030 (USD Million)
Fig. 44 U.S. cancer biopsy market estimates and forecasts for bladder, 2018 - 2030 (USD Million)
Fig. 45 U.S. cancer biopsy market estimates and forecasts for kidney, 2018 - 2030 (USD Million)
Fig. 46 U.S. cancer biopsy market estimates and forecasts for liver, 2018 - 2030 (USD Million)
Fig. 47 U.S. cancer biopsy market estimates and forecasts for pancreas, 2018 - 2030 (USD Million)
Fig. 48 U.S. cancer biopsy market estimates and forecasts for other sites, 2018 - 2030 (USD Million)
Fig. 49 U.S. cancer biopsy market: Application (Cause) outlook and key takeaways
Fig. 50 U.S. cancer biopsy market: Application (Cause) movement analysis
Fig. 51 U.S. cancer biopsy market estimates and forecasts for screening & monitoring, 2018 - 2030 (USD Million)
Fig. 52 U.S. cancer biopsy market estimates and forecasts for diagnostics, 2018 - 2030 (USD Million)
Fig. 53 U.S. cancer biopsy market estimates and forecasts for investigational & translational research, 2018 - 2030 (USD Million)
Fig. 54 U.S. cancer biopsy market estimates and forecasts for pharma & biopharma discovery & development, 2018 - 2030 (USD Million)
Fig. 55 U.S. cancer biopsy market, 2018 - 2030 (USD million)
Fig. 56 Participant categorization - U.S. cancer biopsy market
Fig. 57 Strategy framework - U.S. cancer biopsy market
Fig. 58 Ansoff matrix
Fig. 59 Competition categorization
Companies Mentioned
- Bd (Becton, Dickinson And Company)
- Izi Medical Products
- Johnson & Johnson Services, Inc.
- Argon Medical
- Spectra Medical Devices, Inc.
- Medtronic
- Boston Scientific Corporation
- Conmed Corporation
- Inrad, Inc.
- Thermo Fisher Scientific, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 155 |
| Published | January 2023 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 9.7 Billion |
| Forecasted Market Value ( USD | $ 20.18 Billion |
| Compound Annual Growth Rate | 11.1% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
